Nasus Pharma Ltd. (NSRX) intrinsic value & 10-year financials
Nasus Pharma Ltd. (NSRX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue reached to $1.2B, with an average return on invested capital of -365.1%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $1.2B
- ROIC (10-yr avg)
- -365.1%
- Free cash flow (FY2025)
- -$4.9M
NSRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.2B | -$5.9M | -$0.72 | -$4.9M | -0.4% | -365.1% |
| FY2024 | — | -$1.5M | -$0.22 | — | — | — |
| FY2023 | — | -$1.1M | -$0.20 | — | — | — |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Nasus Pharma Ltd revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Nasus Pharma Ltd has historically struggled to out-earn its cost of capital, averaging just -3.7% ROIC.
Nasus Pharma Ltd capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Nasus Pharma Ltd is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.